CNC vs ELV

Key Takeaways

• Centene Corporation (CNC) and Elevance Health Inc. (ELV) are two of the largest managed care organizations in the United States, yet they occupy meaningfully different positions in the market landscape.
• CNC is heavily concentrated in government-sponsored programs — Medicaid, Medicare, and the Affordable Care Act (ACA) Marketplace — while ELV operates a more diversified platform that includes a commercial employer segment, health benefits, and the Carelon healthcare services division.
• Both companies experienced elevated medical cost trends in 2025, but ELV maintained positive GAAP earnings throughout the year, while CNC posted significant GAAP losses driven largely by a $6.7 billion non-cash goodwill impairment.
• CNC's forward P/E (price-to-earnings) ratio sits near 15.1X, below industry average, reflecting a valuation that embeds considerable recovery uncertainty; ELV trades at a higher multiple but offers stronger baseline profitability and consistent shareholder returns.
• Elevance Health returned $4.1 billion to shareholders through buybacks and dividends in 2025; Centene does not currently pay a dividend and is focused on balance sheet repair after a challenging year.
• For 2026, CNC guides for adjusted diluted EPS (earnings per share) greater than $3.00, while ELV projects adjusted diluted EPS of at least $25.50 — reflecting vastly different earnings bases and market capitalizations.

Introduction

The managed care sector has undergone significant pressure in recent quarters, with elevated medical utilization, shifting Medicaid enrollment dynamics, and regulatory developments reshaping the competitive landscape. Against this backdrop, CNC (Centene Corporation) and ELV (Elevance Health Inc.) represent two distinct approaches to navigating the same headwinds. Centene, with a market capitalization near $19.6 billion, is the largest Medicaid managed care organization in the country and has historically positioned itself as a pure-play government healthcare specialist. Elevance Health, formerly known as Anthem, is a diversified health benefits giant serving approximately 45 million members across commercial, Medicare, Medicaid, and specialty care lines. This comparison examines how these two stocks stack up across profitability, strategic positioning, and risk exposure — relevant for investors weighing value against stability in the healthcare space.

CNC Overview and Recent Performance

CNC (Centene Corporation), headquartered in St. Louis, Missouri, is the nation's largest provider of government-sponsored healthcare, serving roughly 1 in 15 Americans through Medicaid, Medicare, and the ACA Marketplace. The company's core competency lies in managing complex, lower-income populations with high medical needs — a model that generates substantial revenue but yields thinner margins than commercial-focused peers.

In recent weeks, Centene has been navigating the aftermath of a turbulent 2025. The company's full-year results showed total revenues of $194.8 billion and an adjusted diluted EPS of $2.08, but GAAP results were heavily impacted by a $6.7 billion non-cash goodwill impairment charge recorded in the third quarter — triggered by the One Big Beautiful Bill Act and a decline in the company's stock price. Additionally, Centene signed a definitive agreement to divest its remaining Magellan Health businesses, recording a further $513 million impairment charge. These non-cash items pushed full-year GAAP diluted EPS to a loss of $(13.53).

Despite these accounting setbacks, underlying operational trends have shown signs of stabilization. The Medicaid HBR (Health Benefits Ratio — the percentage of premiums spent on medical claims) improved sequentially from 93.4% in Q3 to 93.0% in Q4. CEO Sarah M. London noted that the company enters 2026 with "positive momentum" from decisive actions taken in the second half of 2025. The company guided for 2026 adjusted diluted EPS greater than $3.00, marking an anticipated inflection toward renewed earnings growth. Centene shares, which closed near $39 in recent trading, have declined roughly 33% over the trailing 52-week period, but have shown a recovery of approximately 16% over the most recent three months.

ELV Overview and Recent Performance

ELV (Elevance Health Inc.), based in Indianapolis, Indiana, is one of the largest health benefits companies in the United States, with roughly 45.2 million medical members as of December 31, 2025. The company operates through a diversified structure that spans commercial employer-sponsored plans, Medicare Advantage, Medicaid, and its Carelon services platform — which provides pharmacy benefit management, behavioral health, and post-acute care services.

In recent market activity, Elevance Health reported full-year 2025 operating revenue of $197.6 billion, a 13% increase year over year. Full-year adjusted diluted EPS came in at $30.29, down from $33.04 in 2024, reflecting the broader managed care sector's margin compression from elevated medical cost trends. The full-year benefit expense ratio was 90.0%, an increase of 150 basis points (where one basis point equals 0.01 percentage point) compared to the prior year, driven by higher medical utilization in ACA health plans and Medicare Part D dynamics tied to Inflation Reduction Act changes. Q4 operating margin contracted to just 0.6% on a GAAP basis, though the company emphasized that results were in line with internal expectations.

A key differentiator for ELV is its capital return program. In 2025, the company returned $4.1 billion to shareholders through share repurchases and dividends, including $471 million in buybacks during Q4 alone and a quarterly dividend of $1.71 per share (subsequently raised to $1.72 for Q1 2026). Looking ahead, management guided for 2026 adjusted diluted EPS of at least $25.50 and reaffirmed a long-term earnings algorithm targeting at least 12% adjusted EPS growth by 2027. ELV shares recently traded near $283, approximately 19% below their 52-week high and within a $273-$459 range over the past year.

Trending AI Robots

In an environment where managed care stocks face cross-currents from regulatory shifts, utilization trends, and macroeconomic uncertainty, many traders are turning to AI-driven tools for real-time decision support. Tickeron's Trending AI Robots page offers a curated selection of hundreds of AI-powered trading bots, each designed with distinct trading styles, strategies, and timeframes — from 5-minute intraday scalpers to multi-day swing traders. These bots trade across thousands of tickers and are powered by Tickeron's proprietary Financial Learning Models (FLMs), which continuously ingest market data to identify patterns and generate signals. Among the available bots, annualized return figures have ranged from approximately 34% to over 171% in recent periods, with win rates reaching as high as 100% on select strategies and profit factors exceeding 4.5 in some configurations. Only the bots best suited to prevailing market conditions earn placement in this dynamic, curated section — making it a focused entry point for traders evaluating AI-assisted strategies. Explore the full lineup of Trending AI Robots to see which strategies currently align with your trading objectives.

Head-to-Head Comparison

The most fundamental distinction between CNC and ELV lies in their business model composition. Centene is overwhelmingly dependent on government-sponsored programs, with Medicaid alone accounting for a dominant share of its membership. This concentration provides scale advantages — Centene is the largest Medicaid carrier — but it also creates outsized sensitivity to state-level rate decisions, redetermination cycles, and political shifts around public healthcare funding. Elevance Health, by contrast, derives meaningful revenue from commercial employer-sponsored plans, which tend to carry higher margins and offer more predictable underwriting cycles than government lines.

On profitability metrics, the contrast is stark. ELV produced full-year 2025 adjusted operating income of $7.5 billion on an adjusted operating margin of 3.8%, while CNC's adjusted operating metrics, though not directly comparable due to the goodwill impairment, reflect a company in the midst of a margin recovery effort. ELV's full-year adjusted diluted EPS of $30.29 dwarfs CNC's $2.08, although comparing per-share figures between companies of vastly different share counts and market capitalizations requires context.

Risk profiles also diverge. Centene carries a long-term debt-to-capital ratio of 45.5%, above the industry average, with $17.5 billion in long-term debt. The Magellan divestiture and goodwill impairment also raise questions about acquisition integration risk. Elevance Health maintains a stronger balance sheet with approximately $2.6 billion in parent-company cash and investments plus a $6.7 billion remaining share repurchase authorization. ELV also holds an investment-grade credit profile that supports its capital return strategy.

On growth drivers, Centene is banking on Marketplace expansion — commercial membership grew 29.5% in the first nine months of 2025 — and margin recovery in Medicaid as rate actions catch up with cost trends. Elevance Health is leaning on Carelon's service capabilities, Medicare Advantage membership growth, and pricing discipline across its diversified book. Both face the same macro challenge: medical cost trends that continue to outpace premium rate adjustments in certain segments.

Tickeron AI Verdict

Based on observable factors such as trend consistency, profitability stability, and balance sheet quality, the AI-driven analytical framework would likely favor ELV over CNC in the current market environment. Elevance Health's diversified revenue base, consistent GAAP profitability even during a challenging year, robust shareholder return program, and clearer near-term earnings trajectory provide a more stable foundation for trend-following and momentum-based strategies. While Centene's depressed valuation and early signs of operational improvement may appeal to deep-value and recovery-oriented frameworks — and its 16% three-month rally suggests some investors are positioning for a turnaround — the AI would likely assess ELV's lower volatility, stronger institutional-grade balance sheet metrics, and proactive capital management as better-aligned with probabilistic models that prioritize consistency and downside protection. That said, this assessment is not a prediction, and relative positioning could shift rapidly if Centene's 2026 earnings recovery materializes faster than currently anticipated.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations